Advancing research from University of Pennsylvania, Kira was formed three years ago and made its public debut yesterday with $46m in funding.

Kira Pharmaceuticals, a US-based biotechnology developer focused on immune-mediated diseases that is exploiting research from University of Pennsylvania, emerged from stealth yesterday with a total of $46m in funding. The cash came from 6 Dimensions Capital, an investment firm co-founded by pharmaceutical group WuXi AppTec, and Sinopharm Capital, the corporate venturing arm of pharmaceutical firm…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.